| University Medical Center | |
| 1800 W Charleston Blvd, Las Vegas, Nevada 89102 | |
| (702) 383-2000 | |
| Name | University Medical Center |
|---|---|
| Type | Acute Care Hospital |
| Location | 1800 W Charleston Blvd, Las Vegas, Nevada |
| Ownership | Voluntary non-profit - Other |
| Emergency Services | Yes |
| Medicare ID (CCN) | 290007 |
| NPI Number | 1194165589 |
| Organization Name | UNIVERSITY MEDICAL CENTER |
| Address | 1800 W Charleston Blvd, Las Vegas, NV 89102 |
| Hospital Type | Chronic Disease Hospital |
| Phone Number | 702-383-3860 |
News Archive
Patients seen at private facilities reimbursed by Medicare were more than 550 percent more likely to have routine cataract surgery than those who received their care from the Department of Veterans Affairs, a strong indication that the frequency of cataract surgery may be responsive to financial incentives to either or both the medical facility and the physicians who perform the procedure.
Angiotech Pharmaceuticals, Inc. today announced that it has reached an agreement (the "Second Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement dated October 29, 2010 and amended on November 29, 2010 (as amended, the "Support Agreement").
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.
Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').
The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.
› Verified 4 days ago
| NPI Number | 1205220977 |
| Organization Name | UNIVERSITY MEDICAL CENTER |
| Address | 1800 W Charleston Blvd, Las Vegas, NV 89102 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 702-383-2000 |
News Archive
Patients seen at private facilities reimbursed by Medicare were more than 550 percent more likely to have routine cataract surgery than those who received their care from the Department of Veterans Affairs, a strong indication that the frequency of cataract surgery may be responsive to financial incentives to either or both the medical facility and the physicians who perform the procedure.
Angiotech Pharmaceuticals, Inc. today announced that it has reached an agreement (the "Second Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement dated October 29, 2010 and amended on November 29, 2010 (as amended, the "Support Agreement").
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.
Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').
The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.
› Verified 4 days ago
| NPI Number | 1548393127 |
| Organization Name | UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA |
| Doing Business As | UNIVERSITY MEDICAL CENTER |
| Address | 1800 W. Charleston Blvd., Las Vegas, NV 89102 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 702-383-2000 |
News Archive
Patients seen at private facilities reimbursed by Medicare were more than 550 percent more likely to have routine cataract surgery than those who received their care from the Department of Veterans Affairs, a strong indication that the frequency of cataract surgery may be responsive to financial incentives to either or both the medical facility and the physicians who perform the procedure.
Angiotech Pharmaceuticals, Inc. today announced that it has reached an agreement (the "Second Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement dated October 29, 2010 and amended on November 29, 2010 (as amended, the "Support Agreement").
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.
Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').
The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.
› Verified 4 days ago
| Able to receive lab results electronically | Yes |
| Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Patients seen at private facilities reimbursed by Medicare were more than 550 percent more likely to have routine cataract surgery than those who received their care from the Department of Veterans Affairs, a strong indication that the frequency of cataract surgery may be responsive to financial incentives to either or both the medical facility and the physicians who perform the procedure.
Angiotech Pharmaceuticals, Inc. today announced that it has reached an agreement (the "Second Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement dated October 29, 2010 and amended on November 29, 2010 (as amended, the "Support Agreement").
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.
Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').
The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.
› Verified 4 days ago
Sunrise Hospital And Medical Center Acute Care Hospital Location: 3186 S Maryland Pkwy, Las Vegas, Nevada 89109 Phone: (702) 731-8000 | |
University Medical Center Acute Care Hospital Location: 1800 W Charleston Blvd, Las Vegas, Nevada 89102 Phone: (702) 383-2000 | |
Valley Hospital Medical Center Acute Care Hospital Location: 620 Shadow Lane, Las Vegas, Nevada 89106 Phone: (702) 388-4000 | |
Desert Springs Hospital Acute Care Hospital Location: 2075 East Flamingo Road, Las Vegas, Nevada 89119 Phone: (702) 369-7600 | |
Mountainview Hospital Acute Care Hospital Location: 3100 N Tenaya Way, Las Vegas, Nevada 89128 Phone: (702) 255-5065 | |
Summerlin Hospital Medical Center Acute Care Hospital Location: 657 Town Center Drive, Las Vegas, Nevada 89144 Phone: (702) 233-7500 |